Alastair G Stewart

List of Publications by Year
in descending order

192	7,320	50276	71685
papers	citations	46 h-index	76 g-index

195	195	195	6781
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR study. Journal of Allergy and Clinical Immunology, 2022, 149, 1607-1616.	2.9	7
2	Comprehensive multiplexed superfusion system enables physiological emulation in cell culture: exemplification by persistent circadian entrainment. Lab on A Chip, 2022, 22, 1137-1148.	6.0	2
3	ACE2 Expression in Organotypic Human Airway Epithelial Cultures and Airway Biopsies. Frontiers in Pharmacology, 2022, 13, 813087.	3.5	6
4	Translational Pharmacology and Clinical Trials. , 2021, , .		1
5	Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer. Cancers, 2021, 13, 1154.	3.7	7
6	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological Reviews, 2021, 73, 924-967.	16.0	359
7	Managing Exacerbations in Thunderstorm Asthma: Current Insights. Journal of Inflammation Research, 2021, Volume 14, 4537-4550.	3.5	12
8	High-throughput microfluidic compressibility cytometry using multi-tilted-angle surface acoustic wave. Lab on A Chip, 2021, 21, 2812-2824.	6.0	16
9	Editorial: Accelerated Translation Using Microphysiological Organoid and Microfluidic Chip Models. Frontiers in Pharmacology, 2021, 12, 827172.	3.5	4
10	Cellular Microenvironment Stiffness Regulates Eicosanoid Production and Signaling Pathways. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 819-830.	2.9	25
11	Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Frontiers in Pharmacology, 2020, 11, 603926.	3.5	115
12	On-chip surface acoustic wave and micropipette aspiration techniques to assess cell elastic properties. Biomicrofluidics, 2020, 14, 014114.	2.4	12
13	An Automated Quantitative Method to Analyze Immunohistochemistry and Immunocytochemistry Images. Journal of Engineering and Science in Medical Diagnostics and Therapy, 2020, 3, .	0.5	1
14	Rhythm on a chip: circadian entrainment in vitro is the next frontier in body-on-a chip technology. Current Opinion in Pharmacology, 2019, 48, 127-136.	3.5	11
15	A concise review on cancer treatment methods and delivery systems. Journal of Drug Delivery Science and Technology, 2019, 54, 101350.	3.0	60
16	Editorial overview: Engineering drug discovery technologies: clinical trial on-a-chip. Current Opinion in Pharmacology, 2019, 48, vii-ix.	3.5	0
17	On-chip cell mechanophenotyping using phase modulated surface acoustic wave. Biomicrofluidics, 2019, 13, 024107.	2.4	17
18	A Non-canonical Pathway with Potential for Safer Modulation of Transforming Growth Factor-Î²1 in Steroid-Resistant Airway Diseases. IScience, 2019, 12, 232-246.	4.1	7

#	Article	IF	Citations
19	Safer approaches to therapeutic modulation of TGF-Î² signaling for respiratory disease. , 2018, 187, 98-113.		35
20	Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	23
21	Cortisol limits selected actions of synthetic glucocorticoids in the airway epithelium. FASEB Journal, 2018, 32, 1692-1704.	0.5	10
22	Targeted Graphene Oxide Networks: Cytotoxicity and Synergy with Anticancer Agents. ACS Applied Materials & Interfaces, 2018, 10, 43523-43532.	8.0	18
23	TGFâ€Î²: Master regulator of inflammation and fibrosis. Respirology, 2018, 23, 1096-1097.	2.3	105
24	Casein Kinase 1Î´/Îµ Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-Î² in Pulmonary Fibrosis. Frontiers in Pharmacology, 2018, 9, 738.	3.5	28
25	Casein Kinase 1 delta/epsilon inhibitors: A new class of anti-asthma agents?. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY64-1.	0.0	0
26	Getting the right traction for anti-fibrotic drug evaluation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY80-2.	0.0	0
27	Inhibition of viral infection-induced inflammatory responses by targeting the CLOCK regulator casein kinase 1 Î´/&epsilon. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-5-11.	0.0	0
28	CD151, a laminin receptor showing increased expression in asthmatic patients, contributes to airway hyperresponsiveness through calcium signaling. Journal of Allergy and Clinical Immunology, 2017, 139, 82-92.e5.	2.9	14
29	An Official American Thoracic Society Research Statement: Current Challenges Facing Research and Therapeutic Advances in Airway Remodeling. American Journal of Respiratory and Critical Care Medicine, 2017, 195, e4-e19.	5.6	83
30	The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Scientific Reports, 2017, 7, 41770.	3.3	26
31	Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes. Pharmacological Research, 2017, 119, 278-288.	7.1	25
32	Coal mine dust lung disease in the modern era. Respirology, 2017, 22, 662-670.	2.3	98
33	Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L772-L782.	2.9	30
34	Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential. Scientific Reports, 2017, 7, 43774.	3.3	18
35	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications, 2017, 8, 14232.	12.8	104
36	Translational Pharmacology. Frontiers in Pharmacology, 2017, 8, 8.	3.5	10

#	Article	IF	Citations
37	Glucocorticoid Insensitivity in Virally Infected Airway Epithelial Cells Is Dependent on Transforming Growth Factor-Î² Activity. PLoS Pathogens, 2017, 13, e1006138.	4.7	24
38	Inflammation: maladies, models, mechanisms and molecules. British Journal of Pharmacology, 2016, 173, 631-634.	5.4	28
39	Neonatal pneumococcal colonisation caused by Influenza A infection alters lung function in adult mice. Scientific Reports, 2016, 6, 22751.	3.3	4
40	Graphene Oxide as a Photoluminated Carrier. Materials Today: Proceedings, 2016, 3, 240-244.	1.8	4
41	Cellular Biomechanics in Drug Screening and Evaluation: Mechanopharmacology. Trends in Pharmacological Sciences, 2016, 37, 87-100.	8.7	50
42	Biased signalling from the glucocorticoid receptor: Renewed opportunity for tailoring glucocorticoid activity. Biochemical Pharmacology, 2016, 112, 6-12.	4.4	19
43	Fractionation of graphene oxide single nano-sheets in water-glycerol solutions using gradient centrifugation. Carbon, 2016, 103, 363-371.	10.3	24
44	The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2â€“Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 200-209.	2.9	13
45	Pro-inflammatory mediators increase levels of the noncoding RNA GAS5 in airway smooth muscle and epithelial cells. Canadian Journal of Physiology and Pharmacology, 2015, 93, 203-206.	1.4	44
46	Heterogeneity in mechanisms influencing glucocorticoid sensitivity: The need for a systems biology approach to treatment of glucocorticoid-resistant inflammation. , 2015, 150, 81-93.		29
47	Cardioprotective potential of annexin-A1 mimetics in myocardial infarction. , 2015, 148, 47-65.		59
48	Proteome profiling reveals candidate mediators of TGF-Î²-induced glucocorticoid resistance. , 2015, , .		0
49	Respiratory syncytial virus induces glucocorticoid insensitivity. , 2015, , .		0
50	The Antimalarial Drug Artesunate Inhibits Primary Human Cultured Airway Smooth Muscle Cell Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 451-458.	2.9	23
51	Resolvin D2 Supports MCF-7 Cell Proliferation via Activation of Estrogen Receptor. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 172-180.	2.5	13
52	Bronchial epithelial cells are rendered insensitive to glucocorticoid transactivation by transforming growth factor-Î²1. Respiratory Research, 2014, 15, 55.	3.6	25
53	The plasminogen activation system: new targets in lung inflammation and remodeling. Current Opinion in Pharmacology, 2013, 13, 386-393.	3.5	41
54	Laminin drives survival signals to promote a contractile smooth muscle phenotype and airway hyperreactivity. FASEB Journal, 2013, 27, 3991-4003.	0.5	17

#	Article	IF	Citations
55	Potential for airway smooth muscle as therapeutic target is reflected in the breadth of expertise of next generation scientists. Pulmonary Pharmacology and Therapeutics, 2013, 26, 1-2.	2.6	2
56	Transforming Growth Factorâ€“Î²â€“Induced Differentiation of Airway Smooth Muscle Cells Is Inhibited by Fibroblast Growth Factorâ€“2. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 346-353.	2.9	45
57	Regulation of lung fibroblast activation by annexin A1. Journal of Cellular Physiology, 2013, 228, 476-484.	4.1	50
58	Pulmonary therapeutics: rethinking the regimens and re-imagining the targets. Current Opinion in Pharmacology, 2013, 13, 313-315.	3.5	1
59	Plasminogen-Stimulated Inflammatory Cytokine Production by Airway Smooth Muscle Cells Is Regulated by Annexin A2. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 751-758.	2.9	20
60	Secreted Factors from Human Mast Cells Trigger Inflammatory Cytokine Production by Human Airway Smooth Muscle Cells. International Archives of Allergy and Immunology, 2013, 160, 75-85.	2.1	17
61	Plasminogenâ€stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin <scp>A</scp>2, involving plasminâ€activated cell signalling. British Journal of Pharmacology, 2013, 170, 1421-1435.	5.4	20
62	Total synthesis of the endogenous inflammation resolving lipid resolvin D2 using a common lynchpin. Beilstein Journal of Organic Chemistry, 2013, 9, 2762-2766.	2.2	11
63	More Muscle in Asthma, but Where Did It Come From?. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1035-1037.	5.6	19
64	Reply: Airway Smooth Muscle Hypertrophy and Hyperplasia in Asthma. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 569-569.	5.6	3
65	FcÎµ Receptor Expression in Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 560-560.	2.9	1
66	Transforming growth factorâ€Î² impairs glucocorticoid activity in the A549 lung adenocarcinoma cell line. British Journal of Pharmacology, 2012, 166, 2036-2048.	5.4	38
67	Glucocorticoid-resistant asthma and novel anti-inflammatory drugs. Drug Discovery Today, 2012, 17, 1031-1038.	6.4	47
68	Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacological Research, 2012, 66, 7-18.	7.1	61
69	TGF-Â²-Stimulated Differentiation Of Airway Smooth Muscle Cells Is Inhibited By FGF-2. , 2012, , .		0
70	Plasminogen Evokes Extracelullar Matrix Remodeling By Human Airway Fibroblasts. , 2012, , .		0
71	Transforming Growth Factor Beta (TGF-ÃŸ) Impaired Glucocorticoid Responses In Airway Structural Cells: Known Non-Canonical Pathways Are Not Involved. , 2012, , .		0
72	The Non-Coding RNA Gas5, A Decoy Nucleotide For The Glucocorticoid Receptor, Is Expressed In Human Airway Smooth Muscle And Epithelial Cells. , 2012, , .		0

#	Article	IF	Citations
73	Tumour Necrosis Factor-Â±, Interleukin-4 And Interleukin-13 Impair Glucocorticoid Transactivation In Human Bronchial Epithelial Cells. , 2012, , .		0
74	2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: Vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition. Bioorganic and Medicinal Chemistry, 2012, 20, 2353-2361.	3.0	10
75	In Vitro and In Vivo Evidence for Anti-Inflammatory Properties of 2-Methoxyestradiol. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 962-972.	2.5	33
76	The Non-Estrogenic Steroidal Analogue Of 2-Methoxyestradiol, CP2117, Reduces Lipopolysaccharide Induced Lung Injury: Role Of Annexin-2. , 2011, , .		0
77	Transforming Growth Factor Beta (TGFBeta) Induces Glucocorticoid-Resistance In A549 Adenocarcinoma Cell Line By Reducing Glucocorticoid Receptor Nuclear Localisation. , 2011, , .		0
78	Plasmin Stimulates Airway Smooth Muscle Cells To Proliferate And Produce Interleukin-6. , 2011, , .		0
79	The influence of nitric oxide synthase 2 on cutaneous wound angiogenesis. British Journal of Dermatology, 2011, 165, 1223-1235.	1.5	26
80	R2D₂ for C₄Eo: an â€˜allianceâ€™ of PGD₂ receptors is required for LTC₄ production by human eosinophils. British Journal of Pharmacology, 2011, 162, 1671-1673.	5.4	2
81	Plasminogen Activation by Airway Smooth Muscle Is Regulated by Type I Collagen. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 831-839.	2.9	16
82	Functional Expression of IgG-Fc Receptors in Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 665-672.	2.9	27
83	Secreted Factors From Human Mast Cells Trigger Inflammatory Cytokine Production From Human Airway Smooth Muscle Cells. , 2011, , .		0
84	Collagen remodelling by airway smooth muscle is resistant to steroids and Â2-agonists. European Respiratory Journal, 2011, 37, 173-182.	6.7	43
85	Annexinâ€1 signals mitogenâ€stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. FASEB Journal, 2011, 25, 483-496.	0.5	95
86	Airway smooth muscle remodels pericellular collagen fibrils: implications for proliferation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 298, L584-L592.	2.9	31
87	Fibrillar Collagen Clamps Lung Mesenchymal Cells in a Nonproliferative and Noncontractile Phenotype. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 731-741.	2.9	27
88	Mediators and receptors in the resolution of inflammation: drug targeting opportunities. British Journal of Pharmacology, 2009, 158, 933-935.	5.4	15
89	Airways smooth muscle: The next generation. Pulmonary Pharmacology and Therapeutics, 2009, 22, 351-352.	2.6	3
90	Proliferation is not increased in airway myofibroblasts isolated from asthmatics. European Respiratory Journal, 2008, 32, 362-371.	6.7	52

#	Article	IF	Citations
91	Resistance of fibrogenic responses to glucocorticoid and 2-methoxyestradiol in bleomycin-induced lung fibrosis in miceThis article is one of a selection of papers published in the Special Issue on Recent Advances in Asthma Research.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 727-738.	1.4	24
92	KCa3.1 Ca2+Activated K+Channels Regulate Human Airway Smooth Muscle Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 525-531.	2.9	69
93	Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. European Respiratory Journal, 2007, 29, 834-860.	6.7	344
94	2-Methoxyestradiol â€“ a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discovery Today, 2007, 12, 577-584.	6.4	92
95	The PPARÎ³ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulmonary Pharmacology and Therapeutics, 2006, 19, 39-46.	2.6	43
96	Regulation of human airway mesenchymal cell proliferation by glucocorticoids and Î²2-adrenoceptor agonists. Pulmonary Pharmacology and Therapeutics, 2006, 19, 32-38.	2.6	22
97	Molecular and cellular targets in tissue remodelling. Pulmonary Pharmacology and Therapeutics, 2006, 19, 1-2.	2.6	0
98	Extracellular Matrix, Integrins, and Mesenchymal Cell Function in the Airways. Current Drug Targets, 2006, 7, 567-577.	2.1	66
99	Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signalling. British Journal of Pharmacology, 2006, 149, 365-373.	5.4	43
100	Airway remodelling in asthma: Current understanding and implications for future therapies. , 2006, 112, 474-488.		82
101	Basic mechanisms of development of airway structural changes in asthma. European Respiratory Journal, 2006, 29, 379-389.	6.7	115
102	Stimulusâ€dependent glucocorticoidâ€resistance of GMâ€CSF production in human cultured airway smooth muscle. British Journal of Pharmacology, 2005, 145, 123-131.	5.4	31
103	Refractive index measurement in viable cells using quantitative phase-amplitude microscopy and confocal microscopy. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 65A, 88-92.	1.5	177
104	2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer. Clinical Cancer Research, 2005, 11, 1722-1732.	7.0	47
105	Emigration and immigration of mesenchymal cells: a multicultural airway wall. European Respiratory Journal, 2004, 24, 515-517.	6.7	23
106	CAN WE DIFFERENTIATE BETWEEN AIRWAY AND VASCULAR SMOOTH MUSCLE?. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 805-810.	1.9	14
107	PPARÎ³ ligands, 15â€deoxyâ€Î”^{12,14}â€prostaglandin J₂ and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. British Journal of Pharmacology, 2004, 141, 517-525.	5.4	59
108	Contribution of the p38MAPK signalling pathway to proliferation in human cultured airway smooth muscle cells is mitogen-specific. British Journal of Pharmacology, 2004, 142, 1182-1190.	5.4	40

#	Article	IF	Citations
109	Early Inducible Nitric Oxide Synthase 2 (NOS 2) Activity Enhances Ischaemic Skin Flap Survival. Angiogenesis, 2004, 7, 33-43.	7.2	18
110	On the terminology for describing the length-force relationship and its changes in airway smooth muscle. Journal of Applied Physiology, 2004, 97, 2029-2034.	2.5	81
111	Quantitative phase microscopy: a new tool for measurement of cell culture growth and confluency in situ. Pflugers Archiv European Journal of Physiology, 2004, 448, 462-8.	2.8	32
112	Factors controlling airway smooth muscle proliferation in asthma. Current Allergy and Asthma Reports, 2004, 4, 109-115.	5.3	17
113	Proliferative aspects of airway smooth muscle. Journal of Allergy and Clinical Immunology, 2004, 114, S2-S17.	2.9	198
114	Impact of extracellular matrix and strain on proliferation of bovine airway smooth muscle. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 324-328.	1.9	36
115	Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle. British Journal of Pharmacology, 2003, 138, 865-875.	5.4	50
116	Collagen-induced resistance to glucocorticoid anti-mitogenic actions: a potential explanation of smooth muscle hyperplasia in the asthmatic remodelled airway. British Journal of Pharmacology, 2003, 138, 1203-1206.	5.4	52
117	Differential inhibition of thrombin- and EGF-stimulated human cultured airway smooth muscle proliferation by glucocorticoids. Pulmonary Pharmacology and Therapeutics, 2003, 16, 171-180.	2.6	22
118	Invited Review: Do inflammatory mediators influence the contribution of airway smooth muscle contraction to airway hyperresponsiveness in asthma?. Journal of Applied Physiology, 2003, 95, 844-853.	2.5	68
119	A Randomized Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor Therapy in Severe Sepsis with Respiratory Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 138-143.	5.6	192
120	2-Methoxyestradiol and Analogs as Novel Antiproliferative Agents: Analysis of Three-Dimensional Quantitative Structure-Activity Relationships for DNA Synthesis Inhibition and Estrogen Receptor Binding. Molecular Pharmacology, 2002, 61, 1053-1069.	2.3	59
121	Growing up and advancing in airway smooth muscle research. Trends in Pharmacological Sciences, 2002, 23, 450-451.	8.7	5
122	Antigen-induced airway inflammation in the Brown Norway rat results in airway smooth muscle hyperplasia. Journal of Applied Physiology, 2002, 93, 1833-1840.	2.5	29
123	Angiogenesis in Wound Healing and Surgery. , 2002, , 105-113.		0
124	Airway Wall Remodelling and Hyperresponsiveness: Modelling Remodelling in Vitro and in Vivo. Pulmonary Pharmacology and Therapeutics, 2001, 14, 255-265.	2.6	46
125	Anti-remodelling drugs for the treatment of asthma: requirement for animal models of airway wall remodelling. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 619-629.	1.9	13
126	Muscle cells become necrotic rather than apoptotic during reperfusion of ischaemic skeletal muscle. International Journal of Experimental Pathology, 2001, 80, 169-175.	1.3	22

#	Article	IF	Citations
127	Targeted disruption of the nitric oxide synthase 2 gene protects against ischaemia/reperfusion injury to skeletal muscle. Journal of Pathology, 2001, 194, 109-115.	4.5	40
128	Inducible nitric oxide synthase (iNOS) activity promotes ischaemic skin flap survival. British Journal of Pharmacology, 2001, 132, 1631-1638.	5.4	57
129	Effects of the endothelin receptor antagonist Bosentan on ischaemia/reperfusion injury in rat skeletal muscle. European Journal of Pharmacology, 2001, 424, 59-67.	3.5	22
130	Prior heat stress improves survival of ischemic-reperfused skeletal muscle in vivo. Muscle and Nerve, 2000, 23, 1847-1855.	2.2	46
131	The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. British Journal of Pharmacology, 2000, 131, 17-28.	5.4	69
132	Localization of Inducible Nitric Oxide Synthase to Mast Cells During Ischemia/Reperfusion Injury of Skeletal Muscle. Laboratory Investigation, 2000, 80, 423-431.	3.7	47
133	Neutrophil-independent protective effect of r-metHuG-CSF in ischaemia-reperfusion injury in rat skeletal muscle. International Journal of Experimental Pathology, 2000, 81, 41.	1.3	3
134	Thrombin-stimulated DNA Synthesis in Human Cultured Airway Smooth Muscle Occurs Independently of Products of Cyclo-oxygenase or 5-Lipoxygenase. Pulmonary Pharmacology and Therapeutics, 2000, 13, 241-248.	2.6	3
135	Airway smooth muscle cells. , 2000, , 263-302.		0
136	Î²2-Adrenergic Receptor Agonists and cAMP Arrest Human Cultured Airway Smooth Muscle Cells in the G1 Phase of the Cell Cycle: Role of Proteasome Degradation of Cyclin D1. Molecular Pharmacology, 1999, 56, 1079-1086.	2.3	67
137	Glucocorticoids Inhibit Proliferation, Cyclin D1 Expression, and Retinoblastoma Protein Phosphorylation, but Not Activity of the Extracellular-Regulated Kinases in Human Cultured Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 77-88.	2.9	137
138	Interleukin-1Î± and tumour necrosis factor-Î± modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate. British Journal of Pharmacology, 1999, 126, 1315-1324.	5.4	48
139	Nitric Oxide Synthase-Independent Generation of Nitric Oxide in Rat Skeletal Muscle Ischemia-Reperfusion Injury. Nitric Oxide - Biology and Chemistry, 1999, 3, 75-84.	2.7	25
140	The Survival of Skeletal Muscle Myoblasts in Vitro Is Sensitive to a Donor of Nitric Oxide and Superoxide, SIN-1, but Not to Nitric Oxide or Peroxynitrite Alone. Nitric Oxide - Biology and Chemistry, 1999, 3, 273-280.	2.7	13
141	Continuous plasmafiltration in sepsis syndrome. Critical Care Medicine, 1999, 27, 2096-2104.	0.9	484
142	Organ Ischaemia-reperfusion Injury: The Role and Therapeutic Potential of Nitric Oxide. , 1999, , 367-395.		1
143	A model of bridging angiogenesis in the rat. Journal of Plastic, Reconstructive and Aesthetic Surgery, 1998, 51, 243-249.	1.1	15
144	Influence of Hypoxia and Glucose Deprivation on Tumour Necrosis Factor-Alpha and Granulocyte-Macrophage Colony-Stimulating Factor Expression in Human Cultured Monocytes. Cellular Physiology and Biochemistry, 1998, 8, 75-88.	1.6	40

#	Article	IF	Citations
145	Altered activation of the L-arginine nitric oxide pathway during and after cardiopulmonary bypass. Perfusion (United Kingdom), 1997, 12, 405-410.	1.0	19
146	Activation of the L-arginine nitric oxide pathway in severe sepsis. Archives of Disease in Childhood, 1997, 76, 203-209.	1.9	29
147	A blinded randomised, controlled trial comparing dopamine, noradrenaline, S-methylisothiourea sulphate and volume in a porcine model of endotoxin shock. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 1997, 8, 287-295.	0.1	0
148	Timing of Administration of Dexamethasone or the Nitric Oxide Synthase Inhibitor, Nitro-<scp>l</scp>-Arginine Methyl Ester, is Critical for Effective Treatment of Ischaemia-Reperfusion Injury to Rat Skeletal Muscle. Clinical Science, 1997, 93, 167-174.	4.3	33
149	Ischaemia-reperfusion injury in mouse skeletal muscle is reduced by NÏ‰-nitro-l-arginine methyl ester and dexamethasone. European Journal of Pharmacology, 1997, 332, 273-278.	3.5	37
150	The Role of Potassium Channels in the Inhibitory Effects ofÎ²2-adrenoceptor Agonists on DNA Synthesis in Human Cultured Airway Smooth Muscle. Pulmonary Pharmacology and Therapeutics, 1997, 10, 71-79.	2.6	13
151	HUMAN MONOCYTES MAINTAINED IN CULTURE ACQUIRE FUNCTIONAL RESPONSIVENESS TO PLATELET-ACTIVATING FACTOR THAT IS INDEPENDENT OF INCREASES IN PROTEIN TYROSINE PHOSPHORYLATION. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 563-569.	1.9	1
152	Î²₂â€Adrenoceptor agonistâ€mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of Î²₂â€adrenoceptor stimulation. British Journal of Pharmacology, 1997, 121, 361-368.	5.4	49
153	Role of Tyrosine Phosphorylation in the Signalling of Superoxide Anion Generation in Platelet-Activating-Factor-Stimulated Peritoneal Macrophages. Cellular Physiology and Biochemistry, 1996, 6, 271-282.	1.6	2
154	Effects of low dose intra-arterial monoclonal antibodies to ICAM-1 and CD11/CD18 on local and systemic consequences of ischaemia-reperfusion injury in skeletal muscle. Journal of Plastic, Reconstructive and Aesthetic Surgery, 1996, 49, 202-209.	1.1	20
155	Cool perfusion solutions for skin flaps: a new mixture of pharmacological agents which improves skin flap viability. Journal of Plastic, Reconstructive and Aesthetic Surgery, 1995, 48, 132-144.	1.1	20
156	Regulation of Airway Wall Remodeling: Prospects for the Development of Novel Antiasthma Drugs. Advances in Pharmacology, 1995, 33, 209-253.	2.0	16
157	Tumor necrosis factor alpha modulates mitogenic responses of human cultured airway smooth muscle.. American Journal of Respiratory Cell and Molecular Biology, 1995, 12, 110-119.	2.9	75
158	The effect of glucocorticoids on proliferation of human cultured airway smooth muscle. British Journal of Pharmacology, 1995, 116, 3219-3226.	5.4	101
159	Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: Relationship to elevated cAMP levels. Biochemical Pharmacology, 1995, 49, 1809-1819.	4.4	101
160	Platelet-Activating Factor Biosynthesis in Rat Vascular Smooth Muscle Cells. Journal of Vascular Research, 1994, 31, 144-152.	1.4	18
161	Synergy between tumour necrosis factor Î± and granulocyte-macrophage colony-stimulating factor in neutrophil stimulation. Agents and Actions, 1994, 41, C157-C158.	0.7	1
162	Nitric oxide synthase inhibitor, nitro-iminoethyl-L-ornithine, reduces ischemia-reperfusion injury in rabbit skeletal muscle. Microsurgery, 1994, 15, 703-707.	1.3	35

#	Article	IF	Citations
163	Nitric oxide synthase inhibitors improve skin flap survival in the rat. Microsurgery, 1994, 15, 708-711.	1.3	53
164	MITOGENIC ACTIONS OF ENDOTHELIN-1 AND EPIDERMAL GROWTH FACTOR IN CULTURED AIRWAY SMOOTH MUSCLE. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 277-285.	1.9	58
165	Platelet-activating Factor and WEB-2086 Directly Modulate Rat Cardiomyocyte Contractility. Journal of Molecular and Cellular Cardiology, 1994, 26, 185-193.	1.9	15
166	Inhibition by salbutamol of the proliferation of human airway smooth muscle cells grown in culture. British Journal of Pharmacology, 1994, 111, 641-647.	5.4	105
167	Physiological and pathophysiological roles of nitric oxide. Microsurgery, 1994, 15, 693-702.	1.3	43
168	Airway wall remodelling in asthma: a novel target for the development of anti-asthma drugs. Trends in Pharmacological Sciences, 1993, 14, 275-279.	8.7	91
169	Importance of Basal and Agonist-Stimulated Intracellular Calcium for Superoxide Anion Generation in Peritoneal Macrophages. Cellular Physiology and Biochemistry, 1993, 3, 117-126.	1.6	0
170	Nitrite is produced by elicited but not by circulating neutrophils. Mediators of Inflammation, 1993, 2, 349-356.	3.0	7
171	Albumin inhibits plateletâ€activating factor (PAF)â€induced responses in platelets and macrophages: implications for the biologically active form of PAF. British Journal of Pharmacology, 1992, 107, 73-77.	5.4	37
172	1â€Oâ€hexadecylâ€2â€acetylâ€snâ€glyceroâ€3â€phospho (N,N,N trimethyl) hexanolamine: an analogue of plateletâ€activating factor with partial agonist activity. British Journal of Pharmacology, 1991, 104, 171-177.	5.4	19
173	Platelet-activating factor may participate in signal transduction processes in rabbit leukocytes. Lipids, 1991, 26, 1044-1049.	1.7	12
174	Macrophage activation reduces mobilization of arachidonic acid by guinea-pig and rat peritoneal macrophagesin vitro. Agents and Actions, 1990, 31, 290-297.	0.7	8
175	Platelet-activating factor may act as a second messenger in the release of icosanoids and superoxide anions from leukocytes and endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 3215-3219.	7.1	117
176	CV 6209 IS A NON-COMPETITIVE ANTAGONIST OF PLATELET-ACTIVATING FACTOR RECEPTORS ON GUINEA-PIG RESIDENT PERITONEAL MACROPHAGES. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 813-820.	1.9	4
177	Evidence for an intracellular action of plateletâ€activating factor in bovine cultured aortic endothelial cells. British Journal of Pharmacology, 1989, 96, 503-505.	5.4	28
178	Intracellular plateletâ€activating factor regulates eicosanoid generation in guineaâ€pig resident peritoneal macrophages. British Journal of Pharmacology, 1989, 98, 141-148.	5.4	48
179	ENDOTHELIUM-DERIVED RELAXING FACTOR RELEASED FROM CULTURED CELLS: DIFFERENTIATION FROM NITRIC OXIDE. Clinical and Experimental Pharmacology and Physiology, 1988, 15, 83-92.	1.9	31
180	Characterization of receptors for plateletâ€activating factor on platelets, polymorphonuclear leukocytes and macrophages. British Journal of Pharmacology, 1988, 94, 1225-1233.	5.4	63

#	Article	IF	Citations
181	Vasodilator actions of acetylcholine, A23187 and bradykinin in the guineaâ€pig isolated perfused heart are independent of prostacyclin. British Journal of Pharmacology, 1988, 95, 379-384.	5.4	21
182	Antagonism of vasoconstriction induced by plateletâ€activating factor in guineaâ€pig perfused hearts by selective plateletâ€activating factor receptor antagonists. British Journal of Pharmacology, 1987, 90, 771-783.	5.4	48
183	LIPID MEDIATORS OF ANAPHYLAXIS AND INCREASED AIRWAYS REACTIVITY. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 393-399.	1.9	4
184	Coronary vasoconstriction in the rat, isolated perfused heart induced by plateletâ€activating factor is mediated by leukotriene C₄. British Journal of Pharmacology, 1986, 88, 595-605.	5.4	95
185	Aerosolized and intravenously administered leukotrienes: effects on the bronchoconstrictor potency of histamine in the guineaâ€pig. British Journal of Pharmacology, 1986, 87, 741-749.	5.4	13
186	CHARACTERIZATION OF SUBSTANCE P-INDUCED BRONCHOCONSTRICTION IN THE GUINEA-PIG: A COMPARISON WITH ACETYLCHOLINE. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 223-232.	1.9	6
187	Involvement of capsaicin-sensitive afferent neurones in a vagal-dependent interaction between leukotriene D4 and histamine on bronchomotor tone. Agents and Actions, 1984, 15, 500-508.	0.7	30
188	Attenuation of antigen-induced bronchospasm by fenoterol in the guinea-pig. Agents and Actions, 1984, 14, 31-38.	0.7	3
189	Leukotriene D4 potentiates histamine-induced bronchoconstriction in guinea-pigs. Agents and Actions, 1984, 15, 146-152.	0.7	14
190	Interaction between leukotriene C4 and histamine in the guinea-pig. Prostaglandins, 1984, 28, 644-645.	1.2	0
191	DUAL MODES OF ACTION FOR DISODIUM CROMOGLYCATE IN INHIBITION OF ANTIGEN-INDUCED CONTRACTIONS OF GUINEA-PIG ISOLATED AIRWAYS SMOOTH MUSCLE. Clinical and Experimental Pharmacology and Physiology, 1983, 10, 595-603.	1.9	5
192	Altered energy metabolism and metabolic gene expression associated with increased metastatic capacity identified in MDA-MB-231 cell line variants. Journal of Cancer Metastasis and Treatment, 0, 2018, .	0.8	3